Led by highly experienced people who already worked together in private and public companies bringing drugs through successful clinical development
EXECUTIVE TEAM
STRATEGIC ADVISORS
BOARD OF DIRECTORS
EXECUTIVE TEAM
25 years in biotech, mid-size private & public, C-level roles & Board positions in Drug development, Investment Banking and VC. Track record of fund raising (over $100M raised), partnership deals and M&A, creating an exit for multiple biotechs. Former COO at NLS (NASDAQ:NLSP). Bracco, Quintiles, I-bankers securities, BSI Healthcapital, ADYA
Co-inventor of SF2523, the API of INHAL-101 small molecule while affiliated with SignalRx. Over 35 years experience in drug discovery & development. Inventor of 29 US patents, 4 NMEs through human PoC. CEO & CSO in a small biotech, raising over $25 million in grants and equity. Former C-level in SignalRx, now partially-retired.
Over 23 years experience in leading CMC projects in the pharma industry across a broad range of therapeutic areas including COPD & IPF, with a focus on inhaled products in solid, liquid and semi-solid forms. Proven track record of defining robust strategies and dossiers ensuring successful registration within the EU, US & RoW.
Co-founder and COO at Crystec. Several years experience in tech transfer and manufacturing process scale up in Industry & Academia across China and UK. Director of Healthtech Open Innovation in Bradford and founder of RCUK China Science Bridges programme.
Co-inventor of SF2523, the API of INHAL-101, a small molecule discovered while affiliated with SignalRx. Over 25 years experience in big pharma, mid size and start-up. Biotech cofounder; CEO & COO in revenue stage companies. He serves as SBIR/STTR grant reviewer for the NIH, and was Editor-in-Chief of Molecular Diversity. C-level at SignalRx.
25 years in biotech, mid-size private & public, C-level roles & Board positions in Drug development, Investment Banking and VC. Track record of fund raising (over $100M raised), partnership deals and M&A, creating an exit for multiple biotechs. Former COO at NLS (NASDAQ:NLSP). Bracco, Quintiles, I-bankers securities, BSI Healthcapital, ADYA
Co-inventor of SF2523, the API of INHAL-101 small molecule while affiliated with SignalRx. Over 35 years experience in drug discovery & development. Inventor of 29 US patents, 4 NMEs through human PoC. CEO & CSO in a small biotech, raising over $25 million in grants and equity. Former C-level in SignalRx, now partially-retired.
Over 23 years experience in leading CMC projects in the pharma industry across a broad range of therapeutic areas including COPD & IPF, with a focus on inhaled products in solid, liquid and semi-solid forms. Proven track record of defining robust strategies and dossiers ensuring successful registration within the EU, US & RoW.
Co-founder and COO at Crystec. Several years experience in tech transfer and manufacturing process scale up in Industry & Academia across China and UK. Director of Healthtech Open Innovation in Bradford and founder of RCUK China Science Bridges programme.
Co-inventor of SF2523, the API of INHAL-101, a small molecule discovered while affiliated with SignalRx. Over 25 years experience in big pharma, mid size and start-up. Biotech cofounder; CEO & COO in revenue stage companies. He serves as SBIR/STTR grant reviewer for the NIH, and was Editor-in-Chief of Molecular Diversity. C-level at SignalRx.
Strategic Advisors
Founder ORPHA Strategy, expert for accelerating clinical development, marketing authorization, patient, and market access in orphan indications. Recently involved in clinical development planning in IPF, for an oral autotaxin inhibitor, an inhaled Galectin-3 inhibitor and a late-clinical inhaled prostacyclin analog for IPF.
Co-founder of Crystec and Co-inventor of mSAS. Founder of Bradford Particle Design Ltd, based on supercritical fluids, acquired by Inhale Therapeutics in 2001 for $200M. Has sat on MHRA and EMEA drug review panels. Emeritus Professor of Physical Pharmaceutics, former member of British Pharmacopoeia Commission.
5 years experience as Adya analyst; competitive intelligence and biotech products analysis; former preclinical project manager in NLS.
Scendea is a leading product development and regulatory consulting practice operating globally, with an extensive expertise in inhaled drugs development.
Founder ORPHA Strategy, expert for accelerating clinical development, marketing authorization, patient, and market access in orphan indications. Recently involved in clinical development planning in IPF, for an oral autotaxin inhibitor, an inhaled Galectin-3 inhibitor and a late-clinical inhaled prostacyclin analog for IPF.
Co-founder of Crystec and Co-inventor of mSAS. Founder of Bradford Particle Design Ltd, based on supercritical fluids, acquired by Inhale Therapeutics in 2001 for $200M. Has sat on MHRA and EMEA drug review panels. Emeritus Professor of Physical Pharmaceutics, former member of British Pharmacopoeia Commission.
5 years experience as Adya analyst; competitive intelligence and biotech products analysis; former preclinical project manager in NLS.
Scendea is a leading product development and regulatory consulting practice operating globally, with an extensive expertise in inhaled drugs development.
BOARD OF DIRECTORS
Crystec CEO. Former Licensing Director for AstraZeneca (Crestor acquisition team). Serial enterpreneur. Skilled in strategic marketing, product development & product engineering. Professor of Innovation. UK national lead for Health and Innovation with China.
SignalRX CEO. Experienced Executive and Managing Shareholder with 40 years experience in the practice of law. Skilled in negotiation, arbitration, mediation, complex transactions, legal writing, complex civil litigation, and appeals. Experienced entrepreneur.
25 years in biotech, mid-size private & public, C-level roles & Board positions in Drug development, Investment Banking and VC. Track record of fund raising (over $100M raised), partnership deals and M&A, creating an exit for multiple biotechs. Former COO at NLS (NASDAQ:NLSP). Bracco, Quintiles, I-bankers securities, BSI Healthcapital, ADYA
Crystec CEO. Former Licensing Director for AstraZeneca (Crestor acquisition team). Serial enterpreneur. Skilled in strategic marketing, product development & product engineering. Professor of Innovation. UK national lead for Health and Innovation with China.
SignalRX CEO. Experienced Executive and Managing Shareholder with 40 years experience in the practice of law. Skilled in negotiation, arbitration, mediation, complex transactions, legal writing, complex civil litigation, and appeals. Experienced entrepreneur.
25 years in biotech, mid-size private & public, C-level roles & Board positions in Drug development, Investment Banking and VC. Track record of fund raising (over $100M raised), partnership deals and M&A, creating an exit for multiple biotechs. Former COO at NLS (NASDAQ:NLSP). Bracco, Quintiles, I-bankers securities, BSI Healthcapital, ADYA
©2022 INHALIS
All rights reserved.
Policy / Credits